Work

Abstract PD7-08: Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-pd7-08

Authors: T. Luo, Z. Chunying, X. Liu, D. Zheng, Y. Cheng, Y. Song, P. He, X. Yan, X. Zhong, T. Tian, B. Wei, Y. Xie, J. Chen, Q. Lv

Institutions: Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Xuzhou Medical College

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129605685

Cites:

Cited by:

Related to: